PMID- 28058769
OWN - NLM
STAT- MEDLINE
DCOM- 20171010
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 19
IP  - 5
DP  - 2017 May
TI  - Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 
      receptor agonists: Incidence and consequences.
PG  - 672-681
LID - 10.1111/dom.12872 [doi]
AB  - AIMS: To characterize gastrointestinal adverse events (AEs) with different 
      glucagon-like peptide-1 receptor agonists (GLP-1RAs). METHODS: Two retrospective 
      intention-to-treat analyses of 6-month patient-level data were conducted. Data 
      from three studies comparing exenatide once weekly (n = 617) with exenatide twice 
      daily (n = 606) were pooled, and one (DURATION-6) comparing exenatide once weekly 
      (n = 461) with liraglutide (n = 450) was analysed separately. Patient-reported 
      gastrointestinal AEs were classified as upper or lower, AE incidences and timing 
      were determined, subgroups were analysed, and associations of gastrointestinal 
      AEs with efficacy were examined. RESULTS: Nausea was the most common 
      gastrointestinal AE for all treatments. Fewer exenatide once-weekly-treated vs 
      exenatide twice-daily- or liraglutide-treated patients reported gastrointestinal 
      AEs (34% vs 45% and 25% vs 41%, respectively; both P  < .0001). Fewer exenatide 
      once-weekly-treated patients reported upper plus lower events than 
      liraglutide-treated patients ( P  < .001); the difference between exenatide once 
      weekly and twice daily was not significant. Within each group, more women than 
      men reported gastrointestinal AEs. Events occurrred early and were predominantly 
      mild. Glycated haemoglobin reductions were similar for patients with or without 
      gastrointestinal AEs. Weight loss was greater for patients with gastrointestinal 
      AEs with exenatide once weekly and exenatide twice daily ( P  < .05); no 
      difference was observed in DURATION-6. CONCLUSIONS: Gastrointestinal AEs were 
      less frequent with exenatide once weekly vs exenatide twice daily or liraglutide, 
      and combined upper and lower events occurred less often. Gastrointestinal AEs 
      were typically mild and occurred early. Gastrointestinal AEs did not affect 
      glycaemic control but may be associated with greater weight loss.
CI  - (c) 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Horowitz, Michael
AU  - Horowitz M
AD  - Centre of Research Excellence in Translating Nutritional Science to Good Health, 
      University of Adelaide, Adelaide, South Australia, Australia.
FAU - Aroda, Vanita R
AU  - Aroda VR
AD  - Community Clinical Research Center, MedStar Health Research Institute, 
      Hyattsville, Maryland.
FAU - Han, Jenny
AU  - Han J
AD  - Pharmapace, San Diego, California.
FAU - Hardy, Elise
AU  - Hardy E
AD  - Clinical Research, AstraZeneca, Gaithersburg, Maryland.
FAU - Rayner, Chris K
AU  - Rayner CK
AUID- ORCID: 0000-0002-5527-256X
AD  - Centre of Research Excellence in Translating Nutritional Science to Good Health, 
      University of Adelaide, Adelaide, South Australia, Australia.
LA  - eng
GR  - UL1 TR001409/TR/NCATS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170217
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Incretins)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 839I73S42A (Liraglutide)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Administration Schedule
MH  - Exenatide
MH  - Female
MH  - Gastrointestinal Diseases/*chemically induced/epidemiology/physiopathology
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/prevention & control
MH  - Hypoglycemia/prevention & control
MH  - Incidence
MH  - Incretins/administration & dosage/*adverse effects/therapeutic use
MH  - Intention to Treat Analysis
MH  - Liraglutide/administration & dosage/*adverse effects/therapeutic use
MH  - Male
MH  - Nausea/chemically induced/epidemiology/physiopathology
MH  - Patient Dropouts
MH  - Peptides/administration & dosage/*adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Self Report
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Venoms/administration & dosage/*adverse effects/therapeutic use
MH  - Weight Loss/drug effects
PMC - PMC5412849
OTO - NOTNLM
OT  - GLP-1 receptor agonists
OT  - adverse events
OT  - exenatide
OT  - gastrointestinal disorders
OT  - liraglutide
OT  - type 2 diabetes
EDAT- 2017/01/07 06:00
MHDA- 2017/10/11 06:00
PMCR- 2017/05/02
CRDT- 2017/01/07 06:00
PHST- 2016/10/14 00:00 [received]
PHST- 2016/12/16 00:00 [revised]
PHST- 2016/12/29 00:00 [accepted]
PHST- 2017/01/07 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2017/01/07 06:00 [entrez]
PHST- 2017/05/02 00:00 [pmc-release]
AID - DOM12872 [pii]
AID - 10.1111/dom.12872 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2017 May;19(5):672-681. doi: 10.1111/dom.12872. Epub 2017 
      Feb 17.